Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $3 | $3 | $11 |
| - Cash | $1 | $1 | $1 | $2 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $3 | $2 | $9 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| EBITDA | -$0 | -$1 | -$2 | -$2 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |
| Net Income | -$1 | -$1 | -$2 | -$2 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| % Growth | 42.7% | 63.3% | 9.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |